윤아일린 (한양대학교 의과대학)님 | 한빛사연구자 > 한빛사

Normal-weight MASLD: reclassification, characteristics, and adverse liver outcomes across diverse populations

Clin. Mol. Hepatol., Dec 12 2025, | https://doi.org/10.3350/cmh.2025.0851

2025-12
의약학
한빛사논문

Evaluating Treatment Response Thresholds for Cost-Effective Treatment in Metabolic-Associated Steatotic Liver Disease

Clin. Mol. Hepatol., Nov 03 2025, | https://doi.org/10.3350/cmh.2025.0796

2025-11
의약학
한빛사논문

Efficacy and safety of time-restricted eating in metabolic dysfunction-associated steatotic liver disease

J. Hepatol., Jun 19 2025, S0168-8278(25)02272-X | https://doi.org/10.1016/j.jhep.2025.06.005

2025-06
의약학
한빛사논문

Diagnostic Performance of Noninvasive Tests in Patients with MetALD in a Health Check-up Cohort

J. Hepatol., Jun 13 2024, S0168-8278(24)02313-4 | https://doi.org/10.1016/j.jhep.2024.05.042

2024-06
의약학
한빛사논문

Prevalence, distribution and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings

Hepatology, Nov 01 2023, | https://doi.org/10.1097/HEP.0000000000000664

2023-11
의약학
한빛사논문

Diagnostic Performance of the Fibrosis-4 Index and Nonalcoholic Fatty Liver Disease Fibrosis Score in Lean Adults With Nonalcoholic Fatty Liver Disease

JAMA Netw. Open, 2023 Aug 1;6(8):e2329568 | doi:10.1001/jamanetworkopen.2023.29568

2023-08
의약학
한빛사논문

Letter to the Editor: Is lifestyle modification effective for individuals with high fibrosis-4 index without an additional 2nd tier test?

Hepatology, 2023 Jun 13 | doi: 10.1097/HEP.0000000000000512

2023-06
의약학
한빛사논문

A Reappraisal of the Diagnostic Performance of B-Mode Ultrasonography for Mild Liver Steatosis

Am. J. Gastroenterol., October 31, 2022 | DOI: 10.14309/ajg.0000000000002020

2022-10
의약학
한빛사논문

Nomenclature Dilemma of Metabolic Associated Fatty Liver Disease (MAFLD): Considerable Proportions of MAFLD Are Metabolic Healthy

Clin. Gastroenterol. Hepatol., Available online 30 April 2022 | https://doi.org/10.1016/j.cgh.2022.04.012

2022-04
의약학
한빛사논문

[Letter to the Editor]Do we need a new cut-off for FIB-4 in the metabolic dysfunction-associated fatty liver disease era?

J. Hepatol., Available online 9 June 2021 | https://doi.org/10.1016/j.jhep.2021.05.035

2021-06
의약학
한빛사논문

저자논문

저자논문

저자논문

저자논문

CV 열람하기

연락처 보기